mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.

Schnitzbauer, Andreas A Filmann, Natalie Adam, René Bachellier, Philippe Bechstein, Wolf O Becker, Thomas Bhoori, Sherrie Bilbao, Itxarone Brockmann, Jens Burra, Patrizia Chazoullières, Olivier Cillo, Umberto Colledan, Michele Duvoux, Christoph Ganten, Tom M Gugenheim, Jean Heise, Michael van Hoek, Bart Jamieson, Neville de Jong, Koert P Klein, Christian G Klempnauer, Jürgen Kneteman, Norman Lerut, Jan [UCL] Mäkisalo, Heikki Mazzaferro, Vincenzo Mirza, Darius F Nadalin, Silvio Neuhaus, Peter Pageaux, George-Philippe Pinna, Antonio D Pirenne, Jaques Pratschke, Johann Powel, James Rentsch, Markus Rizell, Magnus Rossi, Giorgio Rostaing, Lionel Roy, André Scholz, Tim Settmacher, Utz Soliman, Thomas Strasser, Simone Söderdahl, Gunnar Troisi, Roberto I Turrión, Victor Sánchez Schlitt, Hans J Geissler, Edward K et al.[show all]

(eng) OBJECTIVE: The aim of this study was to evaluate the survival benefit of sirolimus in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC) (exploratory analysis of the SiLVER-trial). SUMMARY AND BACKGROUND DATA: Patients receiving LT) for HCC are at a high risk for tumor recurrence. Calcineurin inhibitors have shown evidence to promote cancer growth, whereas mammalian target of rapamycin (mTOR) inhibitors like sirolimus have anticancer effects. In the SiLVER-trial (Clinicaltrials.gov: NCT00355862), the effect of sirolimus on the recurrence of HCC after LT was investigated in a prospective randomized trial. Although the primary endpoint of improved disease-free survival (DFS) with sirolimus was not met, outcomes were improved for patients in the sirolimus-treatment arm in the first 3 to 5 years. To learn more about the key variables, a multivariate analysis was performed on the SiLVER-trial data. PATIENTS AND METHODS: Data from 508 patients of the intention-to-treat analysis were included in exploratory univariate and multivariate models for overall survival (OS), DFS and a competing risk analysis for HCC recurrence. RESULTS: Sirolimus use for ≥3 months after LT for HCC independently reduced the hazard for death in the multivariate analysis [hazard ratio (HR): 0.7 (95% confidence interval, CI: 0.52-0.96, P = 0.02). Most strikingly, patients with an alpha-fetoprotein (AFP) ≥10 ng/mL and having used sirolimus for ≥3 months, benefited most with regard to OS, DFS, and HCC-recurrence (HR: 0.49-0.59, P = 0.0079-0.0245). CONCLUSIONS: mTOR-inhibitor treatment with sirolimus for ≥3 months improves outcomes in LT for HCC, especially in patients with AFP-evidence of higher tumor activity, advocating particularly for mTOR inhibitor use in this subgroup of patients. CLINICAL TRIAL REGISTRATION: EudraCT: 2005-005362-36 CLINICALTRIALS.GOV:: NCT00355862.